Effect of Combination Therapy With Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

NCT03794518 Phase 3 UNKNOWN

The prevalence of type 2 diabetes mellitus (T2DM) in Qatar and nations worldwide has increased in recent decades into epidemic proportions. Cardiovascular (CVD) disease is the leading cause of death in T2DM patients. Approximately 80% of T2DM patients will die because of CV cause. Congestive heart failure (CHF) is a major cause of CV death in T2DM, and it also is responsible for significant morbidity and health care expenditure due to high rate of hospitalization for heart failure.

Details

Lead sponsor	Hamad Medical Corporation
Phase	Phase 3
Status	UNKNOWN
Enrolment	648
Start date	2019-03
Completion	2021-12

Conditions

• Risk Reduction

Interventions

• Pioglitazone Plus dapaglifliozin
• Placebo

Primary outcomes

• Time to first hospitalization for heart failure after starting intervention — 3 years
  Hospitalization for heart failure will be defined as a hospitalization \>24 hours requiring intravenous diuretic infusion.

Countries

Qatar